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1. INTRODUCTION 
The design of an oral controlled drug delivery system (DDS) should be 
primarily aimed at achieving more predictable and increased bioavailability of drugs. 
However, the development process is precluded by several physiological difficulties, 
such as an inability to restrain and localize the DDS within desired regions of the 
gastrointestinal (GI) tract and the highly variable nature of gastric emptying process. 
It can be anticipated that, depending upon the physiological state of the subject and 
the design of pharmaceutical formulation, the emptying process can last from a few 
minutes to 12 hours (hr). This variability in turn may lead to unpredictable 
bioavailability and times to achieve peak plasma levels, since the majority of drugs 
are preferentially absorbed in the upper part of the small intestine. Furthermore, the 
relatively brief gastric emptying time (GET) in humans, which normally averages 2–3 
hr through the major absorption zone (stomach or upper part of the intestine), can 
result in incomplete drug release from  the DDS leading to diminished efficacy of the 
administered dose. Thus, control of placement of a DDS in a specific region of the GI 
tract offers numerous advantages, especially for drugs exhibiting an absorption 
window in the GI tract or drugs with a stability problem. Overall, the intimate contact 
of the DDS with the absorbing membrane has the potential to maximize drug 
absorption and may also influence the rate of drug absorption. These considerations 
have led to the development of oral controlled-release (CR) dosage forms possessing 
gastric retention capabilities.1 
Gastro retentive systems can remain in the gastric region for several hours and 
hence significantly prolong the gastric residence time of drugs. Prolonged gastric 
retention improves bioavailability, reduces drug waste, and improves solubility for 
drugs that are less soluble in a high pH environment. It has applications also for local 
drug delivery to the stomach and proximal small intestines. Gastro retention helps to 
provide better availability of new products with new therapeutic possibilities and 
substantial benefits for patients.2 
 
1.1 Basic Gastrointestinal Tract Physiology: 1 
It is well recognized that the stomach may be used as a ‘depot’ for sustained-
release (SR) dosage forms, both in human and veterinary applications. The stomach is 
anatomically divided into three parts: fundus, body, and antrum (or pylorus). The 
proximal stomach, made up of the fundus and body regions, serves as a reservoir for 
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ingested materials while the distal region (antrum) is the major site of mixing 
motions, acting as a pump to accomplish gastric emptying. The process of gastric 
emptying occurs both during fasting and fed states; however, the pattern of motility 
differs markedly in the two states. In the fasted state, it is characterized by an inter-
digestive series of electrical events which cycle both through the stomach and small 
intestine every 2–3 hr. This activity is called the inter-digestive myoelectric cycle or 
MMC, which is often divided into four consecutive phases.  
 Phase I is a quiescent period lasting from 40 to 60 min with rare contractions.  
 Phase II is a period of similar duration consisting of intermittent action 
potentials and contractions that gradually increase in intensity and frequency as 
the phase progresses.  
 Phase III is a short period of intense, large regular contractions lasting from 4 
to 6 min. It is this phase, which gives the cycle the term ‘housekeeper’ wave, 
since it serves to sweep undigested materials out of the stomach and down the 
small intestine. As phase III of one cycle reaches the end of the small intestine, 
phase III of the next cycle begins in the duodenum.  
 Phase IV is a brief transitional phase that occurs between phase III and phase I 
of two consecutive cycles. In the fed state, the gastric emptying rate is slowed 
since the onset of MMC is delayed. In other words, feeding results in a lag time 
prior to the onset of gastric emptying. Overall, the relatively brief GI transit 
time of most drug products, which is approximately 8–12 h, impedes the 
formulation of a once daily dosage form for most drugs. These problems can be 
exacerbated by alteration in gastric emptying that occur due to factors such as 
age, race, sex, and disease states, as they may seriously affect the release of a 
drug from the DDS. It is, therefore, desirable to have a CR product that exhibits 
an extended GI residence and a drug release profile independent of patient 
related variables. 
 
1.2 Factors Affecting Gastric Retention: 3 
 Density – GRT is a function of dosage form buoyancy that is dependent on the 
density. 
 Size – dosage form units with a diameter of more than 7.5mm are reported to 
have an increased GRT compared with those having diameter of 9.9mm. 
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 Shape of dosage form – tetrahedron and ring shaped devices with a flexural 
modulus of 48 and 22.5 kilo pounds per square inch are reported to have better 
GRT ≈ 90% to 100% retention at 24 hr compared with other shapes. 
 Fed or unfed state – under fasting conditions, the GI motility is characterized 
by periods of strong motor activity or MMC that occurs every 1.5 to 2 hr. The 
MMC sweeps undigested material from the end if the timing of administration 
of the formulation coincides with that of the MMC, the GRT of the unit can be 
expected to be very short. However, in the fed state, MMC is delayed and GRT 
is considerably longer. 
 Nature of meal – feeding of indigestible polymers or fatty acid salts can 
change the motility pattern of the stomach to a fed state, thus decreasing the 
gastric emptying rate and prolonging drug release. 
 Caloric content – GRT can be increased by 4 to 10 hr with a meal that is high 
in proteins and fats. 
 Frequency of feed – the GRT can increase by over 400 minutes when 
successive meals are given compared with a single meal due to the low 
frequency of MMC. 
 Gender – mean ambulatory GRT in males (3.4±0.6 hr) is less compared with 
their age and race matched female counterparts (4.6±1.2 hr), regardless of the 
weight, height and body surface). 
 Age – Elderly people, especially those over 70, have a significantly longer 
GRT. 
 Posture – GRT can vary between supine and upright ambulatory states of the 
patient. 
 Concomitant drug administration – anticholinergics like atropine and 
propantheline, opiates like codeine and prokinetic agents like metoclopramide 
and cisapride. 
 Biological factors – diabetes and Crohn’s disease, etc. 
 1.3 Gastroretentive forms: 
1. Floating systems 
2.  High density systems 
3. Expandable systems 
4. Superporous hydrogels 
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5. Mucoadhesive or bioadhesive systems 
6. Magnetic systems 
1. Floating systems 
 These have a bulk density lower than the gastric content. They remain buoyant 
in the stomach for a prolonged period of time, with the potential for continuous 
release of drug. Eventually, the residual system is emptied from the stomach. Gastric 
emptying is much more rapid in the fasting state and floating systems rely heavily on 
the presence of food to retard emptying and provide sufficient liquid for effective 
buoyancy. 
2.High density systems 
      Gastric contents have a density close to water (1.004 g/cm3). When the patient 
is upright small high-density pellets sink to the bottom of the stomach where they 
become entrapped in the folds of the antrum and withstand the peristaltic waves of the 
stomach wall. A density close to 2.5 g /cm3 seems to be necessary for significant 
prolongation of gastric residence time and barium sulphate, zinc oxide, iron powder, 
titanium dioxide are used as excipients. 
Fig:1 Schematic localization of an intragastric floating system and a high-
density system in the stomach 
 
  
3.Expandable systems 
A dosage form in the stomach will withstand gastric transit if it is bigger than 
the pyloric sphincter. However, the dosage form must be small enough to be 
swallowed, and must not cause gastric obstruction either singly or by accumulation. 
Thus, three configurations are required: a small configuration for oral intake, an 
expanded gastroretentive form and a final small form enabling evacuation following 
drug release. Unfoldable and swellable systems have been investigated. Unfoldable 
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systems are made of biodegradable polymers. The concept is to make a carrier, such 
as a capsule, incorporating a compressed system which extends in the stomach. 
 
4.Hydrogel systems 
Although these are swellable systems, they differ sufficiently from the 
conventional types to warrant separate classification. With pore size ranging between 
10 nm and 10 Am, absorption of water by conventional hydrogel is a very slow 
process and several hours may be needed to reach an equilibrium state during which 
premature evacuation of the dosage form may occur. Superporous hydrogels, average 
pore size >100 Am, swell to equilibrium size within a minute, due to rapid water 
uptake by capillary wetting through numerous interconnected open pores  Moreover, 
they swell to a large size and are intended to have sufficient mechanical strength to 
withstand pressure by gastric contraction. 
Fig: 2 i) On the left, superporous hydrogel in its dry (a) and water-swollen (b) 
state. ii) On the right, schematic illustration of the transit of superporous 
hydrogel. 
 
 
 
5.Mucoadhesive or bioadhesive systems: 
  The basis of mucoadhesion is that a dosage form can stick to the mucosal 
surface by different mechanisms. Different theories are invoked to explain these 
mechanisms. Firstly, the electronic theory proposes attractive electrostatic forces 
between the glycoprotein mucin network and the bioadhesive material. Secondly, the 
adsorption theory suggests that bioadhesion is due to secondary forces such as Van 
der Waals forces and hydrogen bonding. The wetting theory is based on the ability of 
bioadhesive polymers to spread and develop intimate contact with the mucus layers, 
and finally, the diffusion theory proposes physical entanglement of mucin strands and 
the flexible polymer chains, or an interpenetration of mucin strands into the porous 
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structure of the polymer substrate. Materials commonly used for bioadhesion are 
poly(acrylic acid) (Carbopol\, polycarbophil), chitosan, Gantrez\ (Polymethyl vinyl 
ether/maleic anhydride copolymers), cholestyramine, tragacanth, sodium alginate, 
HPMC, sephadex, sucralfate, polyethylene glycol, dextran, poly(alkyl cyanoacrylate) 
and polylactic acid. 
 
6.  Magnetic systems: 
  This system is based on a simple idea: the dosage form contains a small 
internal magnet, and a magnet placed on the abdomen over the position of the 
stomach. Although these systems seem to work, the external magnet must be 
positioned with a degree of precision that might compromise patient compliance. 
 
1.4 Mechanism of floating systems 
                 While the system is floating on the gastric the drug is released slowly at the 
desired rate from the system. After release of drug, the residual system is emptied 
from the stomach besides a minimal gastric content needed to allow the proper 
achievement of the buoyancy retention principle, a minimal level of floating force (F) 
is also required to keep the dosage form reliably buoyant on the surface of the meal. 
To measure the floating force kinetics, a novel apparatus for determination of 
resultant weight has been in the literature. The apparatus operates by measuring 
continuously the force equivalent to F (as a function of time) that is required to main 
submerged object. The object floats better if F is on the higher positive side (Fig. 
3(b)). This apparatus helps in optimizing FDDS with respect to stability and 
durabilityof floating forces produced in order to prevent the drawbacks of 
unforeseeable intragastric buoyancy capability variations 19.  
 
F = F buoyancy - F gravity = (Df - Ds) gv--- 
 
Where, F= total vertical force, Df = fluid density, Ds = object density, v = volume and 
g = acceleration due to gravity. 
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Fig: 3. Mechanism of floating systems, GF=Gastric fluid 
 
 
1.5 Technological developments in FDDS:         
     
   Based on mechanism of buoyancy, two distinctly different technologies have 
been utilized in the development of FDDS, which are effervescent system and non 
effervescent system. 
A. Effervescent system: 
Effervescent system include use of gas generating agents, carbonate(sodium 
bicarbonate) and other organic acids (citric acid and tartaric acid) to produce carbon 
dioxide(CO2) gas, thus reducing the density of the system and making it to float on 
the gastric fluid. The effervescent further classified into two types. 
(Ι)  Gas Generating Systems: 
1.   Intra Gastric Single Layer Floating Tablet: 
      These are formulated by the CO2 generating agents and the drug within matrix 
tablet. These have a bulk density lower than gastric fluids and therefore remain 
floating in the stomach unflattering the gastric emptying rate for a prolonged period. 
The drug is slowly released at a desired rate from the floating system and after the 
complete release the residual system is expelled from the stomach. This leads to an 
increase in GRT and better control over fluctuations in plasma drug concentrations. 
 2.  Intra Gastric Bilayered Floating Tablets: 
                These are also compressed tablets and contain two layers for: 
                      Immediate release layer and Sustained release layer   
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Fig: 4 Intra Gastric Bilayered Floating Tablets 
                                           
3.  Multiple Unit type floating pills:  
  These systems consist of sustained release pills as ‘seeds’ surrounded by 
double layers. The inner layer consists of effervescent agents while the outer layer is 
of swellable membrane layer. When the system is immersed in dissolution medium at 
body temperature it sinks at once and then forms swllowen pills like balloon and float 
as the density decreases. 
Fig: 5  multiple-unit oral floating dosage system 
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Fig: 6 Stages of floating mechanism: (A) penetration of water; (B) generation of 
CO2 and floating; (C) dissolution of drug. Key: (a) conventional SR pills; (b) 
effervescent layer; (c) swellable layer; (d) expanded swellable membrane layer; (e) 
surface of water in the beaker 
 
 
ΙΙ.  Volatile liquid/ vacuum containing systems: 
1. Intragastric Floating Gastroretentive Drug Delivery System: 
 These systems can be made to float in the stomach because of floatation 
chamber, which may be a vacuum or filled with air or a harmless gas, while drug 
reservoir is encapsulated inside a microporous compartment. 
Fig: 7 Intragastric floating drug delivery device 
  
 
 
  
                                   
 
 
    
2. Inflatable Gastroretentive Delivery System: 
 In these systems an inflatable chamber is incorporated, which contains liquid 
that gasifies at body temperature to cause the chamber to inflate in the stomach. These 
systems are fabricated by loading the inflatable chamber with a drug reservoir, 
impregnated polymeric matrix, and then encapsulated in a gelatin capsule. After oral 
administration of the capsule dissolve to release the drug reservoir together with the 
inflatable chamber. The inflatable chamber automatically inflates and retains the drug 
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reservoir compartment in floating position. The drug continuously released from the 
reservoir into the gastric fluid. 
Fig: 8 Gastro-inflatable drug delivery device 
 
3.  Intragastric Osmotically Controlled Drug Delivery System: 
 It is comprised of an osmotic pressure controlled drug delivery device and an 
inflatable floating support in a biodegradable capsule. In the stomach, capsule quickly 
disintegrates to release the intragastric osmotically controlled drug delivery device. 
The inflatable support inside forms a deformable hollow polymeric bag that contains a 
liquid that gasifies at body temperature to inflate the bag. The osmotic pressure 
controlled drug delivery device consists of two components; drug reservoir 
compartment and an osmotically active compartment. 
 The drug reservoir compartment is enclosed by a pressure responsive 
collapsible bag, which is impermeable to vapour and liquid and has a drug delivery 
orifice. The osmotically active compartment contains an osmotically active salt and is 
enclosed within a semipermeable housing. In the stomach, the water in the GI fluid is 
continuously absorbed through the semipermeable membrane into osmotically active 
salt. An osmotic pressure is thus created which acts on the collapsible bag and turns in 
forces the drug reservoir compartment reduce its volume and activate the drug 
reservoir compartment to reduce its volume and activate the drug release in solution 
form through the delivery orifice. 
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Fig: 9 Intragastric osmotic controlled drug delivery system 
 
 
 
B. Non Effervescent Systems 
The non effervescent FDDS is based on mechanism of swelling of polymer or 
bioadhesion to mucosal layer in GI tract. The most commonly used excipients in non-
effervescent FDDS are gel forming or highly swellable cellulose type hydrocolloids, 
polysaccharides and matrix forming materials such as polycarbonates, polyacrylates, 
polymethaacrylates, polystyrenes etc. and bioadhesive polymer such as chitosan and 
carbopol                                   
        Fig: 10 Principle of hydrodynamically balanced system.                                                                                    
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The various types of systems are: 
 Single Layer Floating Tablets: 
   They are formed by intimate mixing of drug with a gel forming hydrocolloid, 
which swells in contact with gastric fluid and maintain bulk density of less than unity. 
The air trapped by the swollen polymer confers buoyancy to these dosage forms. 
 Alginate Beads:                                                                                                    
   Multi unit floating dosage forms were developed from freeze dried calcium 
alginate. Spherical beads of approximately 2.5mm diameter can be prepared by 
dropping sodium alginate into aqueous solution of calcium chloride, causing 
precipitation of calcium alginate leading to formation of porous system, which can 
maintain a floating force for over 12 hr. These floating beads gave a prolonged 
residence time of more than 5.5 hr 
 Hollow Microspheres: 
  Multiple-unit hollow microspheres by emulsion solvent diffusion technique 
were prepared with drug and acrylic polymer. These were dissolved in an ethanol-
dichloromethane mixture, and poured into an aqueous solution of PVA with stirring to 
form emulsion droplets. The rate of drug release in micro balloons was controlled by 
changing the polymer to drug ratio. Microballons were floatable in vitro for 12 hours 
when immersed in aqueous media. Radio graphical studies proved that microballons 
orally administered to humans were dispersed in the upper part of the stomach and 
retained there for 3 hours against peristaltic movements. 
 
Drug Candidates Suitable for FDDS 
 Drugs that have narrow absorption window in GIT (e.g. L-DOPA, 
paminobenzoic acid, furosemide, riboflavin)8 
 Drugs those are locally active in the stomach (e.g. misroprostol, antacids). 
 Drugs those are unstable in the intestinal or colonic environment (e.g. 
captopril, ranitidine HCl, metronidazole). 
 Drugs that disturb normal colonic microbes (e.g. antibiotics used for the 
eradication of Helicobacter pylori, such as tetracycline, clarithromycin, 
amoxicillin). 
 Drugs that exhibit low solubility at high pH values (e.g. diazepam, 
chlordiazepoxide, verapamil). 
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Table NO.1: - List of Drugs Formulated as Single and Multiple Unit Forms of 
Floating Drug Delivery Systems 
DosageForm Drugs 
 
Tablets                                                                
Cholrpheniraminemaleate,Theophylline,               
Furosemide, Ciprofloxacin, Captopril,           
Acetylsalicylic acid, Nimodipine,           
Amoxycillin trihydrate, Verapamil HCI  
Isosorbide di nitrate, Isosorbide   
mononitrate, Acetaminophen, Ampicillin,  
Cinnarazine, Dilitiazem Florouracil,            
Prednisolone 
Capsules    Nicardipine, Chlordiazepoxide HCI, 
Furosemide,Misoprostal, Diazepam, 
 Propranlol, Urodeoxycholic             acid. 
 
Microspheres 
Aspirin, Griseofulvin, and p-nitroanilline, 
Ketoprofen, Iboprufen, Terfenadine 
Granules Indomethacin, Diclofenac sodium,   
Prednisolone 
Films Cinnarizine 
 
 
1.6 Advantages and Disadvantages of FDDS 
Advantages of FDDS: 
 Drugs that act locally in the stomach e.g. antacids, antibiotics for microbial 
based ulcer, etc. 
 Drugs that are absorbed primarily in the stomach e.g. Albuterol 
 Drugs those are poorly soluble in alkaline pH. 
 Drugs that have narrow absorption window for absorption of the drugs 
which are absorbed from the proximal part of the small intestine. E.g. 
riboflavin, Levodopa, PABA. 
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 Drugs that degrade in colon e.g. Captopril, Metoprolol. The Floating 
systems are advantageous for drugs meant for local action in the stomach. 
E.g. antacids. 
 Acidic substances like aspirin cause irritation on the stomach wall when 
come in contact with it. Hence FDDS may be useful for the administration 
of aspirin and other similar drugs.  
 The Floating systems are advantageous for drugs absorbed through the 
stomach. E.g. Ferrous salts, antacids. 
  Administration of prolongs release floating dosage forms, tablet or 
capsules, will result in dissolution of the drug in the gastric fluid. They 
dissolve in the gastric fluid would be available for absorption in the small 
intestine after emptying of the stomach contents. 
 It is therefore expected that a drug will be fully absorbed from floating 
dosage forms if it remains in the solution form even at the alkaline pH of 
the intestine. 
 
Disadvantages of FDDS: 
 High variability in gastric emptying time due to variations in emptying 
process. 
 Drugs that cause irritation and leisions to gastric mucosa and unstable in 
gastric fluid cannot be formulated as FDDS 
 Drugs with unpredictable bioavailability, minimum effective concentration 
are achieved slowly. 
 Gastric retention is achieved by many factors such as gastric motility, pH, 
and presence of food. These factors are never constant hence the buoyancy 
cannot be predicted.  
 Floating system is not feasible for thosedrugs that have solubility or 
stability problem in G.I. tract. 
 These systems require a high level of fluid in the stomach for drug delivery 
to float and work efficiently coat, water. 
 The drugs that are significantly absorbed through out gastrointestinal tract, 
which undergo significant first pass metabolism, are only desirable 
candidate. 
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Table No.2: MARKETED PRODUCT OF FDDS: 
 
Sr. 
No. 
Brand Name Delivery 
system 
Drug (dose) Company, 
Country 
1        Madopar Floating, CR 
capsule 
Levodopa (100 
mg), Benserazide 
(25 mg) 
Roche 
Products, USA 
2 Valrelease Floating 
capsule 
Diazepam (15 mg) Hoffmann-
LaRoche, USA 
3 Liquid 
Gaviscon 
Effervescent 
floating liquid 
alginate 
preparation 
Al hydroxide 
(95mg),                      
Mg carbonate     
(358 mg) 
Glaxo Smith-
Kline, India 
4 Topalkan Floating liquid 
alginate 
preparation 
Al-Mg antacid Pierre Fabre 
Drug, France 
5 Almagate Flot 
Coat 
Floating 
dosage form 
Al-Mg antacid ---------- 
6 Conviron Colloidal gel 
forming FDDS 
Ferrous sulphate Ranbaxy, India 
7 Cifran OD Gas-generating 
floating form 
Ciprvenlafaxine hcl  
(1g) 
Ranbaxy, India 
8 Cytotec Bilayer floating 
Capsule 
Misoprostol 
(100mcg/200mcg 
Pharmacia, 
USA 
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2. LITERATURE REVIEW 

 Anil G et al., (2016), prepared a controlled release tablet of Venlafaxine HCl, 
which releases the drug in a sustained manner over a period of 12 hrs. Three 
different viscosity grades of HPMC namely K4M, K15M, K100M were used 
for the tablets. The tablets were prepared by direct compression method and 
then evaluated. A combination of HPMC k100M was found to achieve 
optimum in-vitro buoyancy.1 
 Senthil A et al., (2011), formulated the mucoadhesive microspheres of 
Venlafaxine HCl by single emulsification phase separation technique using 
different volumes of glutaraldehyde as crosslinking agent. The optimized 
formulation was selected based on the percentage of mucoadhesion and 
sphericity of microspheres.the optimized formulation exhibited a high drug 
entrapment efficiency of 70% and a swelling index 1.57%.Mucoadhesion after 
1 hr was 91% and the drug release was also sustained for more than 12hrs. As 
the concentration of the glutaraldehyde increased, the mucoadhesiveness 
decreases and there was no significant effect in time.17  
 Pare. A et al., (2011), developed amlodipine besylate effervescent floating 
tablets by using hydrophilic polymers HPMC and cabopol934 along with 
effervescent agents like sodium bicarbonate and citric acid. It was found that 
carbopol has a negative effect on floating behavior but it was found that 
carbopol has a negative effect on floating behavior but it was used only for the 
drug release retardant charecteristics.1 
 Sreekanth S.K. et al., (2015), prepared floating matrix tablets using HPMC 
K100M as a polymer and sodium bicarbonate as gas generating agent. The 
compressed were then evaluated and there was no interaction between drug 
polymer and excepients, it was found out by IR studies. The in-vitro drug 
release study indicate that the release of the drug depends on the proportion of 
the polymer present in formulation .As the polymer ratio increases the release 
rate of the drug is prolonged.19   
 
 Subash C et al., (2011), designed a controlled release floating tablet of 
Diltiazem HCl using Xanthan gum as a polymer. It was noted that the drug 
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release from the prepared tablets was found to vary with varying concentration 
of the polymer. From the study it was concluded that floating tablets can be 
prepared by using Xanthan gum as a carrier.20 
 Bagherwal A et al., (2013), have formulated the floating tablets of 
Ciprofloxacin HCl with HPMC and carbomer in different proportions (4%, 
8%,9 %)  by direct compression technique. The formulations were then 
evaluated and the mechanism of drug release with all the formulations was 
dominantly diffusion and followed zero order kinetics. The results revealed 
the drug polymer ratio showed greater drug release than other formulations.21 
 Raja et al., (2011), prepared a gastro retentive floating tablets of Glipizide by 
using two different polymers HPMC K4M and HPMC K15M at different 
concentration. It was found that as the concentration of polymer increased, 
floating lag time decreased. Use of high viscosity polymer can also decreases 
the floating lag time and viscosity of the polymer should directly proportional 
relationship with swelling characteristics of tablets.22 
 Garg, R et al.,(2008), scientific and technological advancements have been 
made in the research and development of novel drug delivery systems by 
overcoming physiological troubles such as short gastric residence times and 
unpredictable gastric emptying times. 
 Kotwal K et al., (2012), prepared intragastric buoyant tablets of Amoxicillin 
trihydrate by using different grades of HPMC polymer as gelling agent. It was 
found that hardness of the tablet will affect the buoyancy characteristics of the 
dosage form. The in-vitro release study was concluded that amoxicillin 
releases from the tablet followed peppa’s model with non-fickian diffusion.23   
 Patel VM et al., (2009), were prepared gastroretentive tablets of Verapamil 
HCl by using different hydrocolloid polymer including carbopol (CP 934; CP 
940), hydroxypropaxymethylcellulose (HPMC K4M; HPMC K15M; HPMC 
E15) and xanthangum by direct compression technology. The selected tablets 
containing xanthan gum released approximately 97.89% drug in 24 hours in-
vitro dissolution study, while buoyancy lag time was 24.6 seconds and the 
tablet remained buoyant for more than 24 hours. 24 
 Jaimini M et al., (2007), were formulated Famotidine floating tablets by using 
different grades of methocel (K100, K15M), PVP K-30, gas generating agent 
sodium bicarbonate and citric acid. The floating tablets were evaluated for 
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physicochemical characteristics. All the prepared batches showed good in 
vitro buoyancy. The effect of citric acid on drug release profile and floating 
properties was investigated. The tablets with methocel K100 were found to be 
float for longer duration as compared with formulation containing methocel 
K15.25 
 Prabhu P et al., (2008), were prepared a gastro retentive floating controlled 
drug delivery system containing Glipizide in the form of tablet. Ten 
formulations containing retardant materials such as HPMC4K and eudragit 
RS100, alkalizing agent sodium bicarbonate and other release promoters such 
as sodium lauryl sulphate and polyvinyl pyrrolidone were used. Tablets 
remained buoyant over 8 hours in the release medium, and the amount of 
sodium bicarbonate found to be significant for not only to remaining buoyant 
without causing disintegration of the tablet. Further the selected best 
formulations were compared with the marketed sustained release product and 
found to be comparable release of the drug. All the formulations exhibited 
diffusion dominated drug release.26 
 Deshmukh VN et al., (2009), were prepared theophylline anhydrous 
bioadhesive tablets by using different natural polymers such as xanthan gum, 
locust bean gum, guar gum, karaya gum and their combinations were used to 
formulate matrix tablets. The bioadhesive strength of the tablets were 
measured as the force of detachment against the porcine gastric mucosa. The 
combination of karaya gum: guar gum (6:4) Tablet showed greater biodhesive 
strength as compared with single gum and other gum combination tablets. 
Karaya gum: guar gum loaded tablets were not discharged from the mucous 
membrane and were dissolved in gastric fluid. An increase in the gum 
concentration increases the drug profile beyond 12 hours whereas there is no 
significant effect of gum concentration on bioadhesive strength of the tablet.27 
 Rahman et al., (2006), designed the bilayer floating tablets of captopril using 
HPMC-K15 M, K4M, PVP-K30 and Carbopol 934p alone or in combination 
with the drug in release layer and HPMC K grade, effervescent mixture of 
citric acid and sodium bi carbonate in the floating layer. It was found that 95 
% of drug released in 24 hrs, tablet remained floatable throughout all studies 
and release followed the Higuchi model. In vivo X-ray studies indicated that 
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placebo formulation containing barium sulphate in the release layer 
significantly increased the gastric residence time.28 
 Gambhire  et al., (2007),  Studied on Oral floating matrix tablets of Diltizem 
Hydrochloride by using  Methocel K-100M CR, Compritol 888 ATO, Sodium 
bicarbonate, succinic acid and concluded that the effervescent-based floating 
drug delivery is a promising approach to achieve in vitro buoyancy by using 
gel-forming polymer methocel K 100 CR and gas generating agent sodium 
bicarbonate.  A high level of both Methocel K-100M CR and compritol 888 
ATO favors the preparation of the floating controlled release of DTZ tablets.2 
 Arza RAK et al., (2009), were prepared Swellable and floating 
gastroretentive ciprofloxacin hydrochloride tablet by using a combination of 
hydrophilic polymer (hydroxypropylmethylcellulose), swelling agent 
(crosspovidone, sodium starch glycolate, and croscarmelose sodium) and 
effervescent substance (sodium bicarbonate). A combination of HPMC K100, 
crosspovidone, and sodium carbonate shows the good swelling, drug release, 
and floating character than the marketed product of ciprofloxacin 
hydrochloride CIFRAN OD.30 
 Prajapati ST et al., (2009), were prepared Floating matrix tablets of 
domeperidone were prepared by wet granulation technique, using polymer 
such as HPMC K4M, carbopol 934P and sodium alginate either alone or in 
combination, and other standard excipients. Tablets were evaluated for 
physical characteristics and in vitro release characteristics for 24 hours. 
Floating matrix tablet based on combination of three polymers exhibited 
desired floating and prolonged drug release for 24 hours. Carbopols loading 
showed negative effect on floating properties but were found helpful to control 
the release rate of drug.31 
 Sungthongjeen S et al., (2008), were designed Floating multi-layer coated 
tablets of theophylline based on gas formation. The system consists of a drug 
containing core tablet coated with a protective layer 
(hydroxypropylmethylcellulose), a gas forming layer (sodium bicarbonate) 
and a gas-entrapped membrane, respectively. The properties of acrylic 
polymers (eudragit RL 30D, RS 30D, NE 30D) and ethyl cellulose were 
characterized by the puncture test in order to screen a suitable film for the 
system. Eudragit RL 30D was chosen as a gas-entrapped membrane due to its 
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high flexibility and high water permeability. The obtained tablets enabled to 
float due to the CO2-gas formation and the gas entrapment by polymeric 
membrane.32   
 Singh S et al., (2007), were developed floating matrix tablets of 
metoclopramide hydrochloride using the polymers such as guar gum, karaya 
gum, HPMC E15 alone and in combination with HPMC K15M (HK) and gas 
generating agents such as calcium carbonate and citric acid. Tablets with gas 
generating agent and with HK floated for 24 hours without complete erosion 
and showed slower drug release. This indicates that the gas forming agent 
contributes towards the initial floating of tablets and faster drug release and 
HK for maintaining the integrity of the floating matrix tablet and sustaining 
the drug release.33 
 Vinay pandit et al., (2010), designed gastro retentive form of amoxicillin 
trihydrate floating tablets. The formulations were prepared as matrix tablets in 
the form of non effervescent tablets by using various grades of HPMC. The 
granules were prepared by wet granulation technique and tablets were 
evaluated. The optimized formulation of amoxicillin was found to have 
increased gastric residence prolonging the release of drug with 85% of drug 
release in 6 hrs by diffusion. The mechanism of drug release was found to be 
diffusion and followed combination of zero order and first order kinetics.34 
 
 Mokhopadhayats et al., (2014), formulated floating bioadhesevie tablets of 
ciprofloxacin Hcl by direct compression technique. Tablets were prepared by 
using polymers like HPMC, SCMC, carbopol in different ratios. The 
effervescent base was prepared by using 1: 1 ratio of sodium bycarbonate and 
citric acid. It was observed that tablets with 5% effervescent base shows 
greater control in drug release in comparison to that of 10%.35 
 Atul kumar sahu et al., (2011), prepared buoyant controlled release tablet of 
furosemide containing chitosan and HPMC as a polymer and evaluated. The 
effect of chitosan and HPMC concentration on drug release kinetics and 
buoyancy was also determined. The in vitro drug release of furosemide in all 
the formulations was best explained by zero order equation and followed 
mechanism of non-fickian diffusion. By combining HPMC with chitosan in 
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various blends, the formulation found to be more suitable for oral controlled 
release of furosemide.36 
 Srinivas reddy et al., (2010), developed floating matrix tablets of captopril by 
using natural gumd like xanthine gum, karaya gum, gellan gum along with 
HPMC K4M, PVP K30. The tablets were prepared by direct compression 
using sodium bicarbonate as gas generating agent and evaluated. The linear 
regression analysis and model fitting showed that all this formulation followed 
Higuchi model.37 
 
 
 
AIM AND OBJECTIVE OF STUDY 
Department of Pharmaceutics Page 22 
3. AIM AND OBJECTIVE OF STUDY 
 The aim of this present work is to formulate a gastro retentive floating tablet 
of Venlafaxine HCl by direct compression method using various polymers 
such as Carbopol 934, Xanthan gum,   and HPMC K-100M. 
 Venlafaxine HCl exhibits pH dependent solubility. It is more soluble in acidic 
pH and slightly soluble at neutral or alkaline condition (intestinal 
environment). Hence an attempt will be made to develop gastroretentive 
delivery system of Venlafaxine HCl which would increase the bioavailability 
of Venlafaxine HCl and also to reduce frequency of administration, thereby 
improving patient compliance and therapeutic efficacy.  
Objectives of present work: 
 Formulation and evaluation of sustained release tablet. 
 To study the effect of mixture of drug, hydrophilic and hydrophobic cellulose 
polymers on release rate of sustained release tablet. 
 To reduce the frequency of administration and to improve patient compliance by 
once daily sustained release formulation. 
 To determine the chemical compatibility of formulation containing various ratio 
of polymer and drug. 
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4.  PLAN OF WORK 
 
 To achieve the objectives of the work, the following work was planned an 
undertaken: 
1. Literature survey 
2. Selection of excipients 
3. Formulation of  tablets with different polymers 
4. Optimization of the selected formula 
5. Comparison of in-vitro dissolution profile with that of a marketed formulation. 
6. Completion of data and analysis of results. 
7. Pre- formulation studies for possible drug or polymer interaction by IR 
analysis. 
8. Preparation of floating tablets by direct compression method. 
9. Evaluation of the various properties of floating tablets. 
 Evaluation of precompression parameters such as bulk density, tapped 
density, compressibility index etc. 
 Evaluation of post compression parameters like thickness, hardness, 
friability, drug content, In vitro buoyancy studies. 
10. Drug release study using suitable in-vitro model. 
11. Carry out short term stability studies on the most satisfactory formulation 
 
 
 
 
DISEASE PROFILE 
Department of Pharmaceutics Page 24 
5. DISEASE PROFILE 
Depression is a mood disorder that causes a persistent feeling of sadness and loss 
of interest. Also called major depressive disorder or clinical depression, it affects how 
the person feel, think and behave and can lead to a variety of emotional and physical 
problems. 
Figure No-11 – BRAIN METABOLISM IN BRAIN. 
 
 
Sometimes physical problems can cause depression. But other times, symptoms 
of depression are part of a more complex psychiatric problem. There are several 
different types or subtypes of depression, including: 
Major depressive disorder 
Dysthymia and chronic depression (now called persistent depressive disorder) 
Seasonal affective disorder 
Psychotic depression 
Bipolar depression 
5.1. MAJOR DEPRESSION56 
An individual with major depression, or major depressive disorder, feels a 
profound and constant sense of hopelessness and despair. 
Major depression is marked by a combination of symptoms that interfere with the 
person's ability to work, study, sleep, eat, and enjoy once pleasurable activities. Major 
depression may occur only once but more commonly occurs several times in a 
lifetime. 
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5.2. WHAT ARE THE SYMPTOMS OF MAJOR DEPRESSION57? 
Symptoms of depression include: 
A. Sadness 
B. Irritability 
C. Loss of interest in activities once enjoyed 
D. Withdrawal from social activities 
E. Inability to concentrate 
F. Disrupted sleep 
G. Fatigue or loss of energy 
H. Appetite changes 
I. Thoughts of suicide 
5.3. CAUSES56,57,58 
It's not known exactly what causes depression. As with many mental disorders, 
a variety of factors may be involved, such as: 
 Biological differences. People with depression appear to have physical 
changes in their brains. The significance of these changes is still uncertain, 
but may eventually help pinpoint causes. 
 Brain chemistry. Neurotransmitters are naturally occurring brain chemicals 
that likely play a role in depression. Recent research indicates that changes 
in the function and effect of these neurotransmitters and how they interact 
with neurocircuits involved in maintaining mood stability may play a 
significant role in depression and its treatment. 
 Hormones. Changes in the body's balance of hormones may be involved in 
causing or triggering depression. Hormone changes can result with 
pregnancy and during the weeks or months after delivery (postpartum) and 
from thyroid problems, menopause or a number of other conditions. 
 Inherited traits. Depression is more common in people whose blood 
relatives also have this condition. Researchers are trying to find genes that 
may be involved in causing depression. 
5.4. DYSTHYMIA58 
 Dysthymia, sometimes referred to as a form of chronic depression, is a less severe 
form of depression but the depression symptoms linger for a long period of time, 
typically years. Those who suffer from dysthymia are usually able to function 
normally, but seem consistently unhappy. 
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 It is common for a person with dysthymia to also develop superimposed periods 
of depression, which then lessen without fully going away. This is called "double 
depression." 
 
5.5. TYPES OF DEPRESSION58 
Symptoms caused by major depression can vary from person to person. To 
clarify the type of depression you have, your doctor may add one or more specifiers. 
A specifier means that you have depression with specific features, such as: 
 Anxious distress — depression with unusual restlessness or worry about 
possible events or loss of control 
 Mixed features — simultaneous depression and mania, which includes 
elevated self-esteem, talking too much and increased energy 
 Melancholic features — severe depression with lack of response to 
something that used to bring pleasure and associated with early morning 
awakening, worsened mood in the morning, major changes in appetite, and 
feelings of guilt, agitation or sluggishness 
 Atypical features — depression that includes the ability to be cheered by 
happy events, increased appetite, excessive need for sleep, sensitivity to 
rejection, and a heavy feeling in arms or legs 
 Psychotic features — depression accompanied by delusions or 
hallucinations, which may involve personal inadequacy or other negative 
themes 
 Catatonia — depression that includes motor activity that involves either 
uncontrollable and purposeless movement or fixed and inflexible posture 
 Peripartum onset — depression that occurs during pregnancy or in the 
weeks or months after delivery (postpartum) 
 Seasonal pattern — depression related to changes in seasons and reduced 
exposure to sunlight 
5.6. OTHER DISORDERS THAT CAUSE DEPRESSION SYMPTOMS57,58 
Several other disorders, such as those below, include depression as a 
symptom. It's important to get an accurate diagnosis, so you can get appropriate 
treatment. 
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 Bipolar I and II disorders. These mood disorders include mood swings that 
range from highs to lows. It's sometimes difficult to distinguish between bipolar 
disorder and depression. 
 Cyclothymic disorder. Cyclothymic (sy-kloe-THIE-mik) disorder involves highs 
and lows that are milder than those of bipolar disorder. 
 Disruptive mood dysregulation disorder. This mood disorder in children 
includes chronic and severe irritability and anger with frequent extreme temper 
outbursts. This disorder typically develops into depressive disorder or anxiety 
disorder during the teen years or adulthood. 
 Persistent depressive disorder. Sometimes called dysthymia (dis-THIE-me-uh), 
this is a less severe but more chronic form of depression. While it's usually not 
disabling, persistent depressive disorder can prevent you from functioning 
normally in your daily routine and from living life to its fullest. 
 Premenstrual dysphoric disorder. This involves depression symptoms 
associated with hormone changes that begin a week before and improve within a 
few days after the onset of your period, and are minimal or gone after completion 
of your period. 
 Other depression disorders. This includes depression that's caused by the use of 
recreational drugs, some prescribed medications or another medical condition. 
 
5.7. TREATMENTS AND DRUGS59 
Medications and psychological counseling (psychotherapy) are very effective 
for most people with depression. Your primary care doctor or psychiatrist can 
prescribe medications to relieve symptoms. However, many people with depression 
also benefit from seeing a psychologist or other mental health professional. 
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5.8. CLASSES OF ANTI-DEPRESSANT DRUGS59: 
Table No: 3 CLASSES OF ANTI-DEPRESSANT DRUGS 
S.No Antidepressant type Examples 
1. SSRIs (selective serotonin reuptake inhibitors) Citalopram 
Escitalopram 
Fluoxetine 
Fluvoxamine 
Paroxetine 
Sertraline 
2. SNRIs (serotonin and norepinephrine reuptake 
inhibitors) 
Duloxetine 
Venlafaxine 
Desvenlafaxine 
3. Noradrenaline reuptake inhibitor Reboxetine 
4. TCAs (tricyclic antidepressants) Amitriptyline 
Nortriptyline 
Clomipramine 
Dothiepin 
Doxepin 
Imipramine 
Trimipramine 
5. RIMA (reversible inhibitor of monoamine oxidase) Moclobemide 
6. Tetracyclic antidepressant Mianserin  
7. Tetracyclic analogue of mianserin (sometimes called 
noradrenergic and specific serotonergic 
antidepressant [NaSSA]) 
Mirtazapine 
8. MAOIs (monoamine oxidase inhibitors) Phenelzine 
Tranylcypromine 
9. Melatonergic antidepressant Agomelatine  
 
5.9. SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS)59: 
Serotonin-norepinephrine reuptake inhibitors (SNRIs) are potent inhibitors of 
the reuptake of serotonin and norepinephrine. These neurotransmitters are known to 
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play an important role in mood. SNRIs can be contrasted with the more widely used 
selective serotonin reuptake inhibitors (SSRIs), which act mostly upon serotonin 
alone. 
The human serotonin transporter (SERT) and norepinephrine transporter 
(NET) are membrane proteins that are responsible for the reuptake of serotonin and 
norepinephrine. Balanced dual inhibition of monoamine reuptake can possibly offer 
advantages over other antidepressants drugs by treating a wider range of symptoms. 
 
SNRIs are sometimes also used to treat anxiety disorders, obsessive-compulsive 
disorder (OCD), attention deficit hyperactivity disorder (ADHD), chronic neuropathic 
pain, and fibromyalgia syndrome (FMS), and for the relief of menopausal symptoms. 
5.9.1. HOW DO SNRIS WORK? 
Serotonin and noradrenaline are neurotransmitters — chemicals that relay signals 
between the cells in your brain. SNRIs increase the amount of these two 
neurotransmitters in your brain, and this is how they are thought to improve the 
symptoms of depression. 
5.9.2. Mechanism of action58: 
SNRIs are potent inhibitors of the reuptake of serotonin and norepinephrine. 
These neurotransmitters are known to play an important role in mood. SNRIs can be 
contrasted with the more widely used selective serotonin reuptake inhibitors (SSRIs), 
which act upon serotonin alone. 
The human serotonin transporter (SERT) and norepinephrine transporter (NET) 
are membrane proteins that are responsible for the reuptake of serotonin and 
norepinephrine. Balanced dual inhibition of monoamine reuptake can possibly offer 
advantages over other antidepressant drugs by treating a wider range of 
symptoms.[1] SNRIs, along withselective serotonin reuptake inhibitors (SSRIs) 
and norepinephrine reuptake inhibitors (NRIs), are second-generation antidepressants. 
Over the past two decades, second-generation antidepressants have gradually replaced 
first-generation antidepressants, such as tricyclic antidepressants (TCAs) 
and monoamine oxidase inhibitors (MAOIs) as the drugs of choice for the treatment 
of MDD. This is mainly because of their improved tolerability and safety profile. 
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6. DRUG PROFILE 
3.1 DRUG DATA- VENLAFAXINE HCL: 14, 15 
Venlafaxine HCl is a serotonin and norepinephrine reuptake inhibitors 
 
Molecular formula: CH27NO2 HCl 
 
Molecular weight:  313.87
 
 
Structure:     
                                    
 
Chemical name: (RS)-1-[2-dimethylamino-1-(4-methoxyphenyl)-ethyl]cyclohexanol 
 
Category: Anti-depressant 
 
3.1.1Physico-chemical properties: 
 
Description: white crystalline powder 
Standards: venlafaxine HCl contains not less than 98.5 per cent and not more than of 
101.5 per cent , calculated on the dried basis. 
Solubility: venlafaxine HCl is considered to be soluble in aqueous solutions with pH 
between 2 and 5. It is sparingly to slightly soluble in aqueous solutions with pH 7. 
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Melting point:  Venlafaxine HCl melts at 207-2090C 
Bioavailability: 30% 
Metabolism: Hepatic 
Half life: 4hours 
Execration: Renal 
 
Mechanism of action:  
The mechanism of the antidepressant action of Venlafaxine HCl in humans is 
believed to be associated with its potentiation of neurotransmitter activity in the CNS. 
Preclinical studies have shown that Venlafaxine HCl and its active metabolite, O-
desmethyl venlafaxine (ODV), are potent inhibitors of neuronal serotonin and 
norepinephrine reuptake and weak inhibitors of dopamine reuptake. Venlafaxine HCl 
and ODV have no significant affinity for muscarinic cholinergic, H1-histaminergic, or 
α1-adrenergic receptors in vitro. Pharmacologic activity at these receptors is 
hypothesized to be associated with the various anticholinergic, sedative, and 
cardiovascular effects seen with other psychotropic drugs. Venlafaxine HCl and ODV 
do not possess monoamine oxidase (MAO) inhibitory activity. 
Dosage and Administration: 
Extended release: 
Daily dose: 75-150 mg orally 
Maximum dose (moderately depressed outpatients): 225 mg/day 
Maximum dose (severely depressed inpatients): 375 mg/day 
Adverse effects:  
Suicidal thinking (suicidality), sweating, nausea, constipation, anorexia, 
vomiting, somnolence, dry mouth, dizziness, nervousness, anxiety, tremor, and 
blurred vision. 
Contraindications: 
Venlafaxine HCl hydrochloride tablets must not be used concomitantly in 
patients taking MAOIs or in patients who have taken MAOIs within the preceding 14 
days due to the risk of serious, sometimes fatal, drug interactions with SNRI or SSRI 
treatment or with other serotonergic drugs. These interactions have been associated 
with symptoms that include tremor, myoclonus, diaphoresis, nausea, vomiting, 
flushing, dizziness, hyperthermia with features resembling neuroleptic malignant 
syndrome, seizures, rigidity, autonomic instability with possible rapid fluctuations of 
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vital signs, and mental status changes that include extreme agitation progressing to 
delirium and coma. 
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7. EXCIPIENT PROFILE 
POLYMER PROFILE: 15 
7.1. CARBOPOL934 
1. Nonproprietary Names: 
BP: Carbomer 
USPNF: Carbomer 
JP:  carboxyvinyl polymer 
2.  Synonyms: 
 Carboxypolymethylene , polyacrylic acid. 
3. Functional Category: 
Controlled release agent, stabilizing agent, viscosity enhancing agent, binding agent. 
4. Applications in pharmaceutical formulation or technology: 
They are used in wide range of pharmaceutical applications which provide: 
 Controlled release in tablets 
 Bioadhesion in buccal, ophthalmic, intestinal, nasal, vaginal and 
rectal applications. 
 Thickening at very low concentrations to produce a wide range of viscosities 
and flow properties in topical, lotions, creams and gels, oral suspensions and 
transdermal gel reservoirs. 
 Permanent suspensions of insoluble ingredients in oral suspensions and 
topicals. 
 Emulsifying topical oil-in-water systems permanently, even at elevated 
temperatures, with essentially no need for irritating surfactants. 
5. Description:  
It occurs as odorless, tasteless, fluffy white powder. 
6. Structural Formula:             
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7. Solubility:  
The Carbopol resins are hydrophilic substances that are not soluble in water. 
Rather, these polymers swell when dispersed in water forming a colloidal, mucilage-
like dispersion. 
Carbopol polymers are bearing very good water sorption property. They swell 
in water up to 1000 times their original volume and 10 times their original diameter to 
form a gel when exposed to a pH environment above 4.0 to 6.0. 
8. Viscosity (dynamic):   
Different grades of Carbopol polymers exhibit different rheological properties, 
a reflection of the particle size, molecular weight between crosslinks (Mc), 
distributions of the Mc, and the fraction of the total units, which occur as terminal, i.e. 
free chain ends. The viscosity range of different Carbopol polymers are as follows 
S.No polymer viscosity 
1 Carbopol 934 
NF 
30500 – 39400 
2 Carbopol 934 
p NF 
29400 – 39400 
3 Carbopol  
71G NF 
4000 – 11000 
 
7.2 XANTHAN GUM 
1. Nonproprietary Names: 
BP: Xanthan gum 
USPNF: Xanthani gum 
2.  Synonyms: 
Corn sugar gum; E415; Keltrol; polysaccharide B-1459; Rhodigel; Vanzan NF; 
Xantural 
3. Chemical Name: 
Xanthan gum 
4. Functional Category: 
Stabilizing agent; Suspending agent; Viscosity-increasing agent. 
 
 
EXCIPIENT PROFILE 
Department of Pharmaceutics Page 35 
5. Applications in pharmaceutical formulation or technology: 
Xanthan gum is widely used in oral and topical pharmaceutical formulations, 
cosmetics, and foods as a suspending and stabilizing agent. It is also used as a 
thickening and emulsifying agent. 
6. Description: 
  Xanthan gum occurs as a cream- or white-colored, odorless, free-flowing, fine 
powder. 
7. Typical properties:  
 Acidity/alkalinity: pH = 6.0–8.0 for a 1% w/v aqueous solution. 
 Melting point       : Chars at 270˚C. 
 Solubility             : practically insoluble in ethanol and ether; soluble in cold or 
                                 warm water 
8. Safety:  It is safe when up to 15grams per day are taken. It can cause some side 
effects such as intestinal gas. 
 
7.3. HYDROXYPROPYL METHYLCELLULOSE 
1. Nonproprietary Name: 
BP: Hypromellose 
USP: Hypromellose 
2.  Synonyms: 
Hydroxy Propyl Methyl Cellulose, HPMC, Hypromellosum, Methocel, Methyl 
Cellulose Propylene Glycol Ether, Methyl Hydroxy Propyl Cellulose, Metolose, 
MHPC.  
3. Chemical Name:  Cellulose Hydroxy Propyl Methyl Ether 
4. Empirical Formula and Molecular Weight: 
The PhEur 6.3 describes hypromellose as a partlyO-methylated and O-(2-
hydroxypropylated) cellulose.  Molecular weight is approximately 10 000–1 500 000. 
5. Structural Formula:             
                                                          
 Where, R is H, CH3, or CH3CH(OH)CH2 
                                             Fig: 11 Structure of HPMC 
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6. Applications in Pharmaceutical Formulation or Technology: 
HPMC is widely used in oral, ophthalmic, nasal, and topical pharmaceutical 
formulations. In oral products, hypromellose is primarily used as a tablet binder, in 
film-coating, and as a matrix for use in extended release tablet formulations. 
Concentrations between 2% and 5% w/w may be used as a binder in either wet- or 
dry-granulation processes. High-viscosity grades may be used to retard the release of 
drugs from a matrix at levels of 10–80% w/w in tablets and capsules. Hypromellose is 
also used in liquid oral dosage forms as a suspending and/or thickening agent at 
concentrations ranging from 0.25–5.0%.  
7. Description: 
Hypromellose is an odorless and tasteless, white or creamy-white fibrous or 
granular powder. 
8. Solubility: 
Soluble in cold water, forming a viscous colloidal solution, practically 
insoluble in hot water, chloroform, ethanol (95%), and ether, but soluble in mixtures 
of ethanol and dichloromethane, mixtures of methanol and dichloromethane. 
9. Viscosity (dynamic): 
A wide range of viscosity types are commercially available. Aqueous 
solutions are most commonly prepared. 
Typical viscosity values for 2% (w/v) aqueous solutions of methocel 
(Dow Chemical Co.) viscosities measured at 20ºC 
Methocel grade Viscosity(cps) 
K4 M 4000 
K15M 15000 
K100M 100000 
10. Stability and Storage Conditions: 
Hypromellose powder should be stored in a well-closed container, in a cool, 
dry place. 
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11. Safety: 
Hypromellose is generally regarded as a nontoxic and nonirritating material, 
although excessive oral consumption may have a laxative effect. 
 
7.4.  SODIUM BICARBONATE 
1. Nonproprietary Names: 
BP: Sodium Bicarbonate 
PhEur: Sodium Hydrogen Carbonate 
USP: Sodium Bicarbonate 
2. Synonyms: 
Baking soda, E500, Effer-Soda, Sodium acid carbonate, Sodium hydrogen 
carbonate. 
3. Chemical Name: Carbonic acid monosodium salt 
4. Empirical Formula and Molecular Weight: NaHCO3 and 84.01 
5. Applications in Pharmaceutical Formulation or Technology: 
Sodium bicarbonate is generally used in pharmaceutical formulations as a 
source of carbon dioxide in effervescent tablets and granules. It is also widely used to 
produce or maintain an alkaline pH in a preparation. Recently, sodium bicarbonate 
has been used as a gas-forming agent in alginate raft systems and in floating, 
controlled release oral dosage forms for a range of drugs. Therapeutically, sodium 
bicarbonate may be used as an antacid, and as a source of the bicarbonate anion in the 
treatment of metabolic acidosis.  
6. Descriptions: 
Sodium bicarbonate occurs as an odorless, white, crystalline powder with a 
saline, slightly alkaline taste. 
7. Stability and Storage Conditions: 
Sodium bicarbonate is stable in dry air but slowly decomposes in moist air and 
should therefore be stored in a well-closed container in a cool, dry place. 
8. Incompatibilities: 
Sodium bicarbonate reacts with acids, acidic salts, and many alkaloidal salts, 
with the evolution of carbon dioxide. Sodium bicarbonate can also intensify the 
darkening of salicylates.  
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9. Safety: 
When used as an excipient, sodium bicarbonate is generally regarded as an 
essentially nontoxic and nonirritant material. Administration of excessive amounts of 
sodium bicarbonate may thus disturb the body’s electrolyte balance, leading to 
metabolic alkalosis or possibly sodium overload with potentially serious 
consequences. 
 
7.5.  MICROCRYSTALINE CELLULOSE 
1. Nonproprietary Names: 
BP: Microcrystalline Cellulose 
PhEur: Cellulose, Microcrystalline 
USP-NF: Microcrystalline Cellulose 
2. Synonyms: Avicel, cellulose gel, crystalline cellulose, E460, Emocel, Fibrocel, 
Tabulose, Vivacel.  
3. Functional Category: Tablet and Capsule diluent, suspending agent, adsorbent, 
tablet disintegrant.  
4. Applications: As a diluent in tablets (direct compression and direct compression) 
and capsule formulation. In addition to its use as a diluent, it also has some lubricant 
and disintegrant property.  
5. Description: White-colored, odourless, tasteless crystalline powder composed of 
porous particles. Available in different particle size grades which have different 
properties and applications.  
6. Solubility: Slightly soluble in 5 % w/v NaOH solution, practically insoluble in 
water, dilute acids and most organic solvents.  
7. Stability: It is a stable, though hygroscopic material.  
8. Storage conditions: The bulk material should be stored in a well-closed container 
in a cool and dry place.  
9. Incompatibilities: Incompatible with strong oxidizing agents.  
10. Safety: It is generally regarded as a nontoxic and nonirritant material. 
 
7.6.  MAGNESIUM STEARATE: 
1. Non-proprietary names: 
BP: Magnesium stearate  
JP: Magnesium stearate 
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PhEur: Magnesii stearas  
USPNF: Magnesium stearate 
2. Synonyms: Magnesium octadecanoate, octadecanoic acid magnesium salt and 
stearic acid magnesium salt. 
3. Chemical name: Octadecanoic acid magnesium salt 
4. Structural formula: [CH3 (CH2)16COO] 2 Mg 
5. Molecular weight: 591.34 
6. Functional category: Tablet and capsule lubricant. 
7. Melting point: 117-150 0C 
8. Description: Magnesium stearate is a fine, white, precipitated or milled, 
impalpable powder of low bulk density, having a faint odor of stearic acid and a 
characteristic taste. The powder is greasy to touch and readily adheres to the skin. 
9. Solubility: It is practically insoluble in ethanol (95%), ether and water; slightly 
soluble in warm benzene and warm ethanol (95%). 
10. Applications: It is widely used in cosmetics, foods and pharmaceutical 
formulations. It is primarily used as a lubricant in the manufacturing of tablets and 
capsules, in the concentration of 0.25-5.0%. It is also used in barrier creams. 
11. Stability and storage conditions: It should be stored in a well closed container in 
a cool, dry place. 
 
7.7. TALC 
1. Non-proprietary names: 
BP: Purified talc 
PhEur: Talcum 
USP: Talc 
2. Synonyms: Altalc, powdered talc, purified French chalk, Purtalc, soapstone, 
steatite and Superiore. 
3. Chemical name: Talc 
4. Structural formula: Mg6 (Si2O5)4(OH)4 
5. Functional Category: Anticaking agent, glidant and lubricant. 
 6. Description: 
It is a very fine, white to grayish-white, odorless, impalpable, unctuous, 
crystalline powder. It adheres readily to the skin and is soft to touch and free from 
grittiness. 
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7. Solubility: 
It is practically insoluble in dilute acids and alkalis, organic solvents and 
water. 
8. Applications: 
It was once widely used in oral solid dosage formulations as a lubricant and 
diluent. It is widely used as dissolution retardant in the development of controlled 
release products. In topical preparations, it is used as a dusting powder, although it 
should not be used to dust surgical gloves. It is a natural material it may frequently 
contain micro-organisms and should be sterilized when used as a dusting powder. It is 
additionally used to clarify liquids and is also used mainly for its lubricant properties, 
in cosmetics and food products. 
9. Stability and storage conditions: 
It is a stable material and may be sterilized by heating at 160C for not less 
than 1 hour. It may also be sterilized by exposure to ethylene oxide or gamma 
irradiation. It should be stored in a well closed container in a cool and dry place. 
10. Incompatibilities: 
It is incompatible with quaternary ammonium compounds 
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8. MATERIALS & INSTRUMENTS USED 
 
8.1 MATERIALS USED: 
Table 4: List of chemicals used with their grade and supplier 
S. No. INGREDIENTS AND REAGENTS 
MANUFACTURER / 
SUPPLIERS 
1 Venlafaxine HCl Aurabindo pharma 
2 Carbopol 934p Himedia laboratories 
3 Xanthan gum Himedia laboratories 
4 HPMC K100M Aurabindo pharma 
5 Sodium bicarbonate Nice laboratories 
6 MCC S.D fine chemicals 
7 Magnesium Stearate S.D fine chemicals 
8 Talc Nice laboratories 
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8.2 INSTRUMENTS USED: 
Table 5: Details of Equipments Used 
 
Sr. 
No. NAME OF INSTRUMENT MANUFACTURING COMPANY 
1. Digital Balance Shimadzu Corporation, AW220 &BX6205 
2. Tablet hardness tester Pfizer hardness tester 
3. Friability tester Roche Fribilator 
4. Vernier Caliper Mitutoyo digimatic caliper 
5. Dissolution apparatus USP Electrolab tablet dissolution 
apparatus 
6. Double beam UV Spectrophotometer Lab India UV 3000 
7. Rotary tablet punching machine Proton Multipress 
8. pH meter Systonic 335 
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9. PREFORMULATION STUDIES 
Preformulation studies are carried out in order to evaluate the physical and 
chemical properties of the drug alone and in the combined form with the excipients. 
These studies are important to predict the physical and chemical properties 
and stability of the drug and excipients. 
 
9.1. ORGANOLEPTIC PROPERTIES: 
1. Colour: 
           Take a small quantity of sample and spread it on the white paper and examine 
it visually. 
9.2. PHYSICAL PROPERTIES: 
1. Angle of repose 
The flow characteristics are measured by angle of repose. Improper flow of powder 
is due to frictional forces between the particles. These frictional forces are quantified by 
angle of repose. 
Angle of repose is defined as the maximum angle possible between the surface 
of a file of the powder and the horizontal plan.           
Ø = Tan -1 h/r 
Where, h = height of file 
 R = radius of the base of the pile 
 Ø = angle of repose 
Flow properties and corresponding Angle of Repose 
Table No: 6. Flow properties and corresponding Angle of Repose 
Flow property Angle of Repose (Degree) 
Excellent 25-30 
Good 31-35 
Fair-aid not needed 36-40 
Passable- may hang up 41-45 
Poor- must agitate, vibrate 46-55 
Very poor 56-65 
Very, very poor > 66 
The ideal characteristics of a tablet that make it a popular and acceptable 
dosage form are compactness, physical stability, rapid production capability, chemical 
stability and efficacy. In general above characteristics of tablet are dictated by the 
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quality of the granulation from which it is made. Many formulation and process 
variables involved in the granulation step can affect the characteristics of the 
granulation produced. Therefore various methods to measure certain granulation 
characteristics have been developed to monitor granulation suitability for tablet 
formulation. The main characteristics required to be monitored in granulation are flow 
properties and compressibility. 
 
2. Determinations of bulk density and tapped density: 
An accurately weighed quantity of the powder (w) was carefully poured into 
the graduated cylinder and the volume (v0) was measured. Then  the graduated 
cylinder was closed with lid, set into the density determination apparatus (Bulk 
density apparatus) the density apparatus was set for 500 taps and after that, the 
volume (vf) was measured and continued operation till the two consecutive readings 
were equal. 
The bulk density and tapped density were calculated using the following 
formulas. 
Bulk Density     = W/V0 
Tapped Density = W/Vf 
Where, V0= Initial volume, 
Vf = final volume 
 
3. Compressibility index 
The compressibility Index and Hausner ratio are measures of the property of a 
powder to be compressed. As such, they measure the relative importance of 
interparticulate interactions. In a free flowing powder, such interactions are generally 
less significant, and the bulk and tapped densities will be closer in value. For poorer 
flowing materials, there are frequently greater inter particle interactions, and a greater 
difference between the bulk and tapped densities will be observed. These differences 
are reflected in the compressibility index and the Hausner ratio. 
The compressibility index and hausner ratio are calculated by measuring the 
values for bulk density (P bulk) and tapped density (P tapped) as follows: 
Compressibility index =        P tapped – P bulk/P tappedX 100 
 
Hausner ratio   = P tapped / P bulk 
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Scale of flowability 
Table No: 7. Scale of flowability 
Compressibility index (%) Flow character Hausner Ratio 
≤ 10 Excellent 1.10-1.11 
11-15 Good 1.12-1.18 
16-20 Fair 1.19-1.25 
21-25 Passable 1.26-1.34 
26-31 Poor 1.35-1.45 
32-37 Very poor 1.46-1.59 
>38 Very, very poor >1.60 
 
4. Melting point: 
It is the characteristic to test the purity of the sample. 
Procedure: 
Take a small quantity of sample into the fusion tube. Place the tube in the 
mating point apparatus containing castor oil. Increase the temperature of castor oil 
gradually and note the temperature starts to melt and when all the powder completely 
melts. 
 
9.3. Solubility: 
Take a small quantity of sample and add the solvent until the sample 
completely dissolves. It is examined visually for the presence of any un dissolved 
particles. 
 
9.4.Drug-excipient compatibility studies: 
 Drug-excipient compatibility studies are important to know the interaction 
between drug and excipients and in between excipients of the formulation, which 
could later affect the stability of the formulation and may interfere with the 
pharmacological action of the drug. 
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The physical examination of the formulation is done when alone and in 
combination with the excipients. If there is any change in the physical appearance, 
shows that there is interaction. 
 But some substances do not show any physical changes when combined in a 
formulation, for such FT-IR (Fourier transform-infrared) studies are conducted. 
 
Procedure by FT-IR studies: 
The FT-IR studies are conducted for Venlafaxine HCL and mixture of 
Venlafaxine HCL and excipients by preparing dispersion in potassium bromide discs. 
The peaks are obtained and compared with the standards by superimposing these 
spectra and observed for any difference in shape and size of spectrum. If there is any 
significant change represents interaction between drug and excipients.  
 
9.5.PREPARATION OF STANDARD CURVE 
DETERMINATION OF λmax OF Venlafaxine Hcl IN ACID BUFFER (pH 1.2) 
Fig12:  Spectrum of Venlafaxine HCl 
 
 Venlafaxine HCl drug solution in pH 1.2(0.1N HCl) was scanned using UV-
Spectrophotometer between the range 210-400nm using pH 1.2 as blank and the 
maximum absorbance (λ max) was found at 224nm. 
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Preparation of 0.1 M Hydrochloric acid: 
Accurately measure 8.5 ml of hydrochloric acid and sufficient water to make 
upto 1000 ml. 
Preparation of stock solution: 
Accurately weigh 100 mg of Venlafaxine HCL and transfer it to a 100 ml 
volumetric flask. Then make up the volume to 100 ml with 0.1 M Hcl. 
Preparation of standard solution: 
Pipette out 10 ml of the above solution and transfer it to a 100 ml volumetric 
flask. Then make up the volume to 100 ml with 0.1 M Hcl. Then from the standard 
stock solution withdraw 2ml, 4ml, 6ml, 8ml, and 10ml into five 100 ml different 
volumetric flasks. Then make up the volume to 100 ml with 0.1M Hcl to get 2, 4, 6, 8, 
10 µg/ml concentration.  
CALIBRATION CURVE OF VENLAFAXINE HCL: 
The absorbance of the prepared stock solutions was measured at 224 nm in an 
UV spectrophotometer. Plot a graph between concentration (in µg/ml) vs absorbance 
(in nm) on X-axis and Y-axis respectively. 
 
Table no. 8. Calibration curve of Venlafaxine HCL 
 
 
 
 
 
 
 
 
S.no. Concentration(in µg/ml) Absorbance  (in nm) 
1. 0 0.000 
2. 2 0.136 
3. 4 0.305 
4. 6 0.462 
5. 8 0.612 
6. 10 0.754 
R2 0.9992 
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Fig.no.13 .calibration curve of Venlafaxine HCL 
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10. FORMULATION 
TABLE NO. 9: The Composition of Tablets Prepared Using Venlafaxine HCl 
INGREDIENTS / 
FORMULATION F1 F2 F3 F4 F5 F6 F7 F8 F9 
Venlafaxine HCl 150 150 150 150 150 150 150 150 150 
Carbopol 934p 20 25 30 - - - - - - 
Xanthan gum - - - 80 95 110 - - - 
HPMC K100M - - - - - - 60 70 80 
Sodium 
bicarbonate 7 7 7 7 7 7 7 7 7 
MCC 147 142 137 87 72 57 107 97 87 
Magnesium 
Stearate 3 3 3 3 3 3 3 3 3 
Talc 3 3 3 3 3 3 3 3 3 
Total 330 330 330 330 330 330 330 330 330 
 
10.1. STEPS INVOLVED IN FORMULATION 
Each tablet containing 300 mg Venlafaxine HCl were prepared by direct 
compression method. Accurately weighed amount of drug Venlafaxine HCl,  
Carbopol 934 p, Xanthan gum, HPMC K100M, PEO, Sodium CMC were mixed 
geometrically in a mortar. Then binder PVP K 30, MCC, Sodium bicarbonate, 
Sodium bicarbonate and MCC are passed through the sieve and thoroughly mixed for 
15 minutes. The powder blend then lubricated with Talc and magnesium stearate for 2 
minutes and compressed on a tablet punching machine using 9 mm punches. The total 
weight of the tablet is 330 mg. 
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11. EVALUATION 
11.1. Pre-compression parameters: 
1. Angle of repose: 
Take a small quantity of powder (5 gm) in a cone shaped funnel and fix it to a 
holder at an appropriate height say 6 cm above the surface. Place a graph sheet below 
it. The sample was passed slowly through the funnel. The height of the powder heap 
was formed. Then measure the circumference of the heap by drawing with the pencil 
on the graph sheet. The radius of the heap was measured. The angle of repose is 
calculated by using the following formula. This is repeated five times for accurate 
results. 
Ø = Tan -1 h/r  
Where,      h = height of file 
R= radius of the base of the pile 
Ø = angle of repose 
The results were tabulated in table. 
 
2.Bulk density and Tapped density: 
Weigh a small quantity of the powder (w) was carefully poured into the 
graduated cylinder and the volume (v0) was measured. Then the graduated cylinder 
was closed with lid, set into the density determination apparatus (Bulk density 
apparatus) set for 500 taps and after that, the volume (vf) was measured and continued 
operation till the two consecutive readings were equal. 
The bulk density and tapped density were calculated using the following 
formulas. 
Bulk Density     = W/V0 
Tapped Density = W/Vf 
Where, V0= Initial volume, 
Vf = final volume 
The results were tabulated in table. 
 
3. Compressibility index and Hausner ratio: 
The compressibility index and hausner ratio are calculated by measuring the 
values for bulk density (P bulk) and tapped density (P tapped) as follows: 
Compressibility index =     P tapped – P bulk/P tappedX 100 
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Hausner ratio   = P tapped / P bulk 
The results were tabulated in table. 
 
11.2. EVALUATION OF FORMULATED TABLETS OF VENLAFAXINE HCL 
All the formulated sustained release tablets were evaluated for following 
official and unofficial parameters. 
1. Weight Variation 
Twenty tablets were randomly selected from each batch and individually 
weighed. The average weight and standard deviation of twenty tablets was calculated. 
The batch passes the test for weight variation test if not more than two of the 
individual tablet weight deviate from the average weight by more than the percentage 
shown in a none deviate by more than twice the percentage shown. 
% deviation= tablet weight-average weight x 100 
                           Tablet weight 
Observation: 
The average weight and standard deviation of the tablets of each batch were 
given. 
Weight variations Specification  
Table No: 10. Weight variations Specification 
Average weight of tablets(X mg) Percentage deviation 
130 or less ±10 
130 to 324 ±7.5 
More than 324 ±5 
2. Dimensions 
Control of physical dimension of the tablets thickness is essential for 
consumer acceptance and to maintain tablet to tablet uniformity. The dimensional 
specifications were measured using digital Vernier calipers. The thickness of tablets is 
mostly related to the tablet hardness can be used as initial control parameter. 
Six tablets were randomly selected from each batch and their thickness was 
measured by using Digital Vernier caliper. 
 
3. Hardness60 
It is determined to get perfect compactness during shipping, coating, and 
packaging and to get proper shape and design. Hardness was measured by using 
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hardness tester. (Pfizer hardness tester) for each batch six tablets were tested. The 
force required to break the tablet is recorded by the unit is Kg/cm2. 
Observation: 
The measured hardness of tablets of each batch was range from 6-16Kg/cm2. 
 
4. Friability 
Twenty tablets were weighed and placed in the Roche friabilator and apparatus 
was rotated at 25 rpm for every 4 minutes. After revolution the tablets were dedusted 
and weighed again. The percentage friability was measured using the formula, 
%F= {1-(Wt /W)} x 100 
                    Where,    %F=friability in percentage 
                                     W=initial weight of tablets after revolution 
Observation: 
All the formulated batches were found under acceptable limit of 0.1- 0.6 as specified 
in IP. 
 
5. Buoyancy Lag Time61 
It is determined in order to assess the time taken by the dosage form to float on 
the top of the dissolution medium, after it is placed in the medium. These parameters 
can be measured as a part of the dissolution test. 
The results were tabulated in table. 
 
6. Floating Time62 
Test for buoyancy is usually performed in SGF-Simulated Gastric Fluid 
maintained at 370C. The time for which the dosage form continuously floats on the 
dissolution media is termed as floating time. 
7. Dissolution study: 
Preparation of buffer: 
 Measure 8.5 ml of Hcl in a 1000 ml volumetric flask and make up the volume 
to 1000 ml using distilled water. 
Requirements: 
Medium: 0.1N Hcl 
Volume: 900 ml 
Apparatus: USP II (paddle) 
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RPM: 50 
Time: upto 12 hrs 
Temperature: 370 c + 0.50c 
λmax :  224 nm 
Perform the test on six tablets one tablet in each dissolution vessel containing 900 ml 
of 0.1 N Hcl maintained at 370c + 0.50c. at specific time withdrawn required amount 
of sample and replace same amount of 0.1N Hcl(maintain sink condition), then 
absorbance was taken and calculate percentage release. 
% purity = absorbance * 900 * dilution * 100 
           Slope * 1000 * label claim 
 
8. Assay: 
        Crush 20 tablets and weigh equivalent to 20 mg Venlafaxine HCL and dissolved 
in 0.1N Hcl and make up the volume to 100 ml. From that, withdraw 10 ml and 
diluted to 100 ml with 0.1 N Hcl. Read the absorbance at 232 nm in UV 
spectrophotometer. 
9. Kinetics of drug release 
 The invitro dissolution profile of all batches were fitted to Zero 
order,  
first order, Higuchi model and Koresmeyer-Peppas model to ascertain the kinetic 
modeling of drug release. Correlation coefficient (R2) values were calculated for 
linear curves obtained by the regression analysis of the above plot. 
 
 Zero-order kinetic model – Cumulative % drug released Vs time. 
 First-order kinetic model – log cumulative % drug remaining Vs time. 
 Higuchi model - Cumulative % drug released Vs square root of time. 
 Korsmeyer-Peppas model - log cumulative % drug released Vs log 
time. 
Zero-order kinetics 
 Zero order release would be predicted by the following equation: 
   At = Ao-Kot 
 At -  Drug release at time‘t’ 
 Ao - Initial drug concentration 
 Ko - Zero-order rate constant (hr-1) 
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 When the data plotted as cumulative % drug release Vs time and the plot is 
linear, then the data obeys zero-order equal to Ko. 
 
First order kinetics: 
First order release would be predicted by the following equation: 
 
Log C = log Co – Kt / 2.303 
 
 C - Amount of drug remained at time‘t’ 
 Co - Initial drug concentration 
 K - First-order rate constant (hr-1) 
When data is plotted as log cumulative % remaining Vs time yields a straight 
line, and then the release obeys first order kinetics.  The constant ‘K’ obtained by 
multiplying 2.303 with the slope values. 
 
Higuchi’s Model: 
Drug release from the matrix devices by diffusion has been described by  
Following Higuchi’s classical diffusion equation: 
 
  Q  = [D/ (2A-εCS) CSt] ½ 
 
 Q  -  Amount of drugreleased at time‘t’ 
 D  - Diffusion coefficient of the drug in the matrix 
 A  - Total amount of drug in unit volume of matrix 
 CS - The solubility of drug in the matrix 
  - Porosity of the matrix 
  - Tortuosity 
 t - Time at which amount of drug released 
When the data is plotted as Cumulative % drug released Vs square root of 
time yields a straight line, indicating that drug release follows diffusion 
mechanisms.  The slope is equal to ‘K’. 
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Korsmeyer – Peppas model: 
 To study the mechanism of drug release from the microspheres, the invitro 
release data were fitted to the well known exponential equation (Korsmeyer – 
Peppas model), which is often used to describe the drug release behaviour from 
polymeric systems. 
Mt/Mα = Ktn 
 
 
Mt/Mα  - The fraction of drug released at time‘t’ 
     K-Constant incorporating structural and geometrical characteristics    
of the drug/polymer system 
 N-Diffusion exponent related to the mechanism of drug release 
When the data plotted as log % drug released Vs log time yields a   straight 
line with a slope equal to ‘n’ and the ‘K’ can be obtained from y-intercept.  
 
Mechanism of drug release as per Korsmeyer-Peppasequation / Peppas 
model 
 
Table. No. 11: Mechanism of drug release 
 
 
S.No n value Drug release 
1 0 –0.5 Fickian release 
2 0.5 – 1.0 Non-Fickian release 
3 >1.0 Class II transport 
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12.RESULT AND DISCUSSION 
12.1. Preformulation studies: 
12.1.1. Organoleptic properties: 
The tests were performed as per the procedure. The results were tabulated 
below. 
Table.no.12. organoleptic properties 
Test Specifications/limits Observations 
Colour White to off-white powder 
white to off-white 
crystalline solid 
odour Odourless Odourless 
The result complies as per specifications. 
12.1.2. Physical properties: 
Angle of repose: 
It was determined as per procedure. The results were tabulated below. 
Table.no.13. flow properties 
Material Angle of repose 
Venlafaxine 
HCl 
27.230 
The results show that the drug having poor flow. 
Bulk density and tapped density: 
          It was determined as per procedure. The results were tabulated below. 
Table no. 14.bulk density and tapped density 
Material Bulk density(gm/ml) Tapped density(gm/ml) 
Venlafaxine HCl 0.53 0.56 
Powder compressibility: 
              It was determined as per procedure. The results were tabulated below. 
Table no. 15.powder compressibility 
Material Compressibility index Hausner’s ratio 
Venlafaxine HCl 6.84 1.06 
Melting point: 
               It was determined as per procedure. The results were tabulated below. 
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Table no.16. Melting point 
Material Melting point range Result 
Venlafaxine HCl 215-2170c 2150c 
           The result indicates that the Venlafaxine HCl drug was pure one. 
12.1.3. SOLUTION PROPERTIES 
Solubility: 
          It was determined as per procedure. The results were tabulated below. 
Table no.17 . Solubility 
Material Test Specification observation 
Venlafaxine 
HCl 
Solubility soluble in water, DMSO Complies 
 
         The result complies as per specification. 
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8.3 FTIR STUDIES 
TABLE NO. 18 Compatibility Studies of Venlafaxine HCl with Excipients 
 
SL. 
NO 
 
Excipients 
Drug/ 
Excipients 
Ratio 
Physical 
Description 
Initial 
350C ± 20C  / 60% ± 5% 
RH 
1 
Week 
2 
Week 
3 
Week 
1 Venlafaxine HCl - White 
crystalline 
powder 
            
* 
           
* 
            
* 
2 Drug + 
carbopol934 
1:1 
 
White 
crystalline 
powder 
 
* 
 
* 
 
* 
3 Drug + xanthan 
gum 
1:1 White 
crystalline 
powder 
 
* 
 
* 
 
* 
4 Drug + HPMC 
k100M 
1:1 White 
crystalline 
powder 
 
* 
 
* 
 
* 
       * indicates no incompatibility. 
 
Fig14:  FTIR Spectroscopy of pure drug 
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Fig15:  FTIR Spectroscopy of Carbopol934 
 
Fig16:  FTIR Spectroscopy of Xanthan gum 
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Fig17:  FTIR Spectroscopy of HPMC K100M 
Fig18:  FTIR Spectroscopy of pure drug+ Carbopol 934 
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Fig19:  FTIR Spectroscopy of pure drug+ Xanthan gum 
 
    
Fig20:  FTIR Spectroscopy of pure drug+ HPMC K100M 
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Table No. 19: Comparison of the peak of functional groups of Venlafaxine HCl 
observed in IR spectra of compatibility studies: 
 
 
S. No 
 
Types of 
vibrations 
 
IR 
absorption 
Ranges 
(cm-1) 
 
 Drug 
(cm-1) 
Physical mixture(drug + 
polymer) 
Drug              
+       
xanthan 
gum 
Drug      
+ 
carbopol 
934 
Drug                     
+   
HPMC 
K100M 
1  Aromatic   
C-H 
stretching 
3000-2850 2939.6 2936.5 2942.5 2945.4 
2 Aromatic 
C=C 
stretching 
1680-1600 1647.2 1642.9 1632.4 1648.2 
3 O-H 
stretching 
3400-3600 3349.5 3349.5 3437.2 3332.1 
4 C-O 
stretching 
1300-1000 1243.16 1245.9 1246.6 1247.2 
5 N-H 
stretching 
(1˚ & 
2˚amine) 
3500-3100 3349.5 3349.5 3437.2 3332.1 
6 C-N 
stretching 
1350-1000 1308.7 1302.9 1304.5 1302.9 
 
 
 In order to check the integrity of the drug in the formulation, FTIR spectra of 
pure drug(Venlafaxine HCl), Carbopol 934, HPMC K100M, Xanthan gum and 
mixture of drug with the above polymers were taken and compared. The FTIR 
spectrum of Venlafaxine HCl reveal the presence of peaks at 2939.6 due to the 
presence of C-H stretching, 1647.2 due to the presence of C=C aromatic 
stretching, 3349.5 due to the presence of    O-H stretching, 1243.16 due to the 
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presence of C-O stretching, 3349.5 due to the presence of N-H stretching, 
1308 due to the presence of C-N stretching. 
 Major frequencies of functional groups of pure drug remain intact in powder 
containing Carbopol 934, HPMC K100M and Xanthan gum. Hence there is no 
major interaction between the drug and polymers used in the study. 
8.4 EVALUATION PARAMETERS: 
6.4.1 Pre Compression Parameters 
Table No.20: Evaluation parameters of powder blend 
Formulation Angle of 
repose 
Bulk 
density(gm/cc) 
Tapped 
density(gm/cc) 
Compressibility 
index (%) 
F1 29 01l±0.1 0.36±0.004 0.41±0.018 11.8±0.8 
F2 300 3l±0.2 0.37±0.001 0.44±0.017 13.4±0.8 
F3 320 1l±0.5 0.38±0.005 0.44±0.004 13.3±0.6 
F4 300 61±0.3 0.35±0.005 0.41±0.003 14.2±1.4 
F5 320 81±0.5 0.34±0.004 0.40±0.018 14.8±1.2 
F6 330 81±0.1 0.35±0.002 0.42±0.001 16.2±0.7 
F7 280 11±0.7 0.35±0.002 0.40±0.005 12.6±0.9 
F8 280 51±0.3 0.36±0.003 0.41±0.002 12.7±1.1 
F9 310 21±0.1 0.36±0.005 0.42±0.004 14.2±1.3 
 
 Floating tablets of Venlafaxine HCl was developed to increase the gastric 
residence time of the drug, so that they can be retained in the stomach for 
longer time and help in controlled release of drug up to 12 hrs. 
  Different grades of viscosities of Carbopol 934, xanthan gum, HPMC K100M 
polymers is known to be beneficial in improving floating property and release 
charecteristics. 
 The pre- compression parameters obtained for all formulations are tableted in 
the table no 13. The value of angle of repose was found to be in the range of 
28011 to 33081. This indicates good flow property of powder blend. Carr’s 
index value ranges between 11.8 to 16.2% indicates that the powder blend 
have the required flow property for direct compression.  
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8.4.2 Post Compression Parameters: 
Table no.21: Evaluation parameters of formulations 
Formulation Thickness   
( mm) 
Hardness   
(kg/cm2) 
Friability        
(%) 
Average  
weight 
variation(mg) 
Drug 
content 
(%) 
F1 3.76±0.04 5.33±0.02 0.65±0.07 331.2±1.3 98.06 
F2 3.68±0.07 5.61±0.05 0.59±0.09 330.7±1.4 98.39 
F3 3.62±0.02 5.44±0.03 0.53±0.05 331.5±1.7 97.22 
F4 3.71±0.04 5.48±0.01 0.54±0.11 330.2±2.1 99.02 
F5 3.67±0.09 5.86±0.04 0.47±0.08 329.8±2.3 97.18 
F6 3.63±0.11 6.14±0.02 0.47±0.12 331.3±2.1 97.56 
F7 3.74±0.02 5.42±0.03 0.57±0.04 329.2±1.4 97.19 
F8 3.76±0.01 5.57±0.01 0.54±0.07 328.7±1.8 98.45 
F9 3.69±0.05 5.72±0.05 0.53±0.06 331.4±1.2 98.28 
 
 The floating tablets were prepared by direct compression method using the 
polymers Carbopol 934, Xanthan gum, HPMC K100M to provide sufficient 
drug release retardation and provide sufficient buoyancy to the tablets .The 
results have shown in the table no.14. 
 The prepared floating tablets were evaluated for thickness, hardness, friability, 
average weight variation, drug content, all the studies were performed in 
triplicates and the results were expressed in ± standard deviation.  
 The measured hardness for the tablets for each batch arranged between 5.33 to 
6.14 kg/cm, this ensures the good handling characteristics of all the batches. 
 The % friability was less than 1% in all the formulations ensuring that the 
tablets were mechanically stable. 
 The weight variation for different formulations was found to be 328.7 to 
331.4, indicates consistency in each batch. 
 The drug content was found to be 97.19 to 98.45, with low standard deviation 
indicates batch to batch consistency. 
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8.5 SWELLING INDEX: 
 
Table no.22: Swelling index (%) of formulations 
 
Time  
(hrs) 
Formulations 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
1 26.6 23.3 22.8 40.7 37.2 36.4 17.8 19.4 22.1 
2 87.45 74.77 41.2 73.25 74.5 68 34.7 36.1 36.5 
4 158.8 149.7 65.7 163.7 160.3 130.7 59.4 64.2 72.3 
6  154.5 114.8   154.2 89.2 98.2 112.7 
8   133.4    122.3 114.5 128.7 
10        126.9 132.3 
12         135.1 
 
            Fig 21:  Graph for comparison of swelling index of all the formulation          
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      Swelling index for all the formulations was carried out in the 0.1N HCl. The 
formulations showed different indices in the swelling media and it is shown in the 
table. Tablets containing carbopol934 and HPMC K100M showed maximum swelling 
in 12 hr with sharp increase up to 8 hr this may due to increased concentration of 
HPMC K100M which retain water and form thick swollen mass.  
8.6 BUOYANCY STUDIES: 
Table no. 23: Buoyancy studies of formulations 
Formulation 
code 
Floating lag time (sec) Floating duration 
(hrs) 
F1 52 4.5 
F2 58 6 
F3                             76 8 
F4 29 4.5 
F5 36 5 
F6 34 6.5 
F7 34 8.5 
F8 32 10 
F9 39 12 
 
Fig 22:  Floating duration of Formulation F1 - F9 
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Fig 23:  In vitro buoyancy studies of optimized formulation 
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 The in-vitro floating behavior of the tablets was studied by placing them in 
beaker containing 0.1 N HCl (pH 1.2). The gas generating agents immediately 
evolves carbon dioxide in presence of HCl solution generating sufficient 
porosity which helped the dosage unit to float. Formulation F1-F3 prepared 
with carbopol934p started floating after 52 seconds and remains buoyant for             
8 hr till they were completely eroded. 
 On the other hand formulation F4-F6 prepared with Xanthan gum which 
shows a floating time of 6.5 hrs and formulation of F7-F9 prepared with 
HPMC K100M show decrease in floating lag time to 34 seconds and increased 
floating duration time to 12 hrs. This might be due to high viscosity polymer 
HPMC K100M maintains the integrity of the tablets for longer duration by 
reducing the effect of erosion thus resulting in increase in floating time. The 
results are shown in table no.16.Thus it can be concluded that the batch 
containing HPMC polymers showed good floating lag time and total floating 
time.                                           
8.7 In-Vitro DRUG RELEASE STUDIES: 
 In-vitro drug release studies were carried out using USP dissolution apparatus 
type II at 50 rpm. The dissolution medium consisted of 900 ml of pH 1.2 acid buffer 
(0.1N HCl), maintained at 37 + 0.50C. The drug release at different time intervals was 
measured using an ultraviolet visible spectrophotometer at 224 nm.  
Table no.24: Percentage drug release of formulations 
Time 
(hrs) 
Formulations 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
1 24.87 22.92 20.06 38.34 32.28 27.54 23.46 22.43 18.84 
2 58.16 55.27 48.07 62.15 45.38 41.15 39.87 31.11 24.18 
4 96.53 71.18 69.18 98.1 94.19 76.77 67.82 53.67 43.67 
6  96.11 78.92   96.13 82.09 65.28 61.08 
8   98.33    97.12 76.59 72.49 
10        98.76 83.54 
12         98.03 
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                  Fig24:  In-vitro dissolution profile of F1 to F3 formulations. 
 
 
                           
 
Fig25:  In-vitro dissolution profile of F4 to F6 formulations. 
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Fig26:  In-vitro dissolution profile of F7 to F9 formulations. 
 
Fig27:  In-vitro dissolution profile of F7 to F9 formulations. 
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release of formulation in F9. As per the results of dissolution study the 
formulations F1-F9 the drug release was sustained for 4 to 12hr. 
 All the formulations were designed as dosage form for 12 hours.  In order to 
check the 100% dissolution release profile, formulations were subjected to 
dissolution studies for 12 hours. Among the nine formulations F9 was best and 
shows 98.03% drug release in the end of 12 hours. 
 It is evident from the in-vitro dissolution data that increase in HPMC K100M 
concentration decreases  the release rate this might be due to increase in 
diffusional path length, which the drug molecule may have to travel. . So, 
formulation F9 was selected as the optimized formulation. The results are 
shown in table no.17. 
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8.8 RELEASE KINETICS: 
Table No. 25 Model fitting for formulation F-9 
Time 
(Hr) 
cumulative 
% drug 
released 
% drug 
remaining 
Square 
root 
time 
log Cumu 
% drug 
remainining 
log 
time 
log 
Cumu 
% drug 
released 
0 0 100 0.000 2.000 0.000 0.000 
1 18.84 81.16 1.414 1.909 0.301 1.275 
2 24.18 75.82 2.000 1.880 0.602 1.383 
4 43.67 56.33 2.449 1.751 0.778 1.640 
6 61.08 38.92 2.828 1.590 0.903 1.786 
8 72.49 27.51 3.162 1.439 1.000 1.860 
10 83.54 16.46 3.464 1.216 1.079 1.922 
12 98.03 1.97 3.464 0.294 1.079 1.991 
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Fig28:   Zero order kinetic model of F9 
 
 
 
Fig29:  First order kinetic model of F9 
 
 
 
 
y = 7.77x + 8.4652 
R² = 0.9811 
0
20
40
60
80
100
120
0 2 4 6 8 10 12 14
cu
m
u
la
ti
v
e
 %
 d
ru
g
 r
e
le
a
se
d
 
Time (Hr) 
Zero-order kinetic model  
y = 0.1158x + 2.1326 
R² = 0.8278 
0.000
0.500
1.000
1.500
2.000
2.500
0 2 4 6 8 10 12 14
lo
g
 C
u
m
u
 %
 d
ru
g
 r
e
m
a
in
in
in
g
 
Time (Hr) 
First-order kinetic model  
RESULTS AND DISCUSSION 
Department of Pharmaceutics Page 74 
Fig30: Higuchi model of F9 
 
 
 
Fig31: Korsmeyer-Peppas model of F9 
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 The mechanism of drug release is predicted by using Korsmeyer–Peppas 
equation. The n value of optimized formulation F9 is 0.66 respectively and is 
between “0.45 to 0.85”. This indicates that the drug release depends on 
swelling, diffusion, and erosion. All formulations follow the non-
Fickian/anomalous type of diffusion. 
8.9 STABILITY STUDIES: 
Table no. 26: Stability studies of optimized formulation F9 
 
Time    
( days) 
25oC ± 2oC/60% RH ± 5% RH, 30oC ± 2oC/65% RH ± 5% RH,  40oC ± 
2oC/75% RH ± 5% RH 
Hardness(kg/cm2) Drug content 
(%) 
%  Drug release 
Total floating 
time 
30 5.56 98.45 98.34 >12 
60 5.56 98.42 98.27 >12 
90 5.48 98.18 98.71 >12 
 
 Stability studies were carried out on selected formulations (F9) as per ICH 
guidelines. There was not much variation in matrix integrity of the tablets at 
all the temperature conditions. There was no significant changes in drug 
content, physical stability, hardness, friability, drug release, floating lag time 
(Table 20) for the selected formulation F8 after 90 days at 25oC± 20C / 60% ± 
5% RH, 300C ± 20C / 65% ±5% RH and 400C ± 20 / 75% ± 5% RH. 
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8.10 COMPARISON WITH MARKETED PRODUCT:     
Table no.27: Comparative studies with optimized formulation 
Time(hrs) Cumulative % drug release 
F9 Marketed product 
1 18.84 27.64 
2 24.18 37.18 
4 43.67 56.79 
6 61.08 74.28 
8 72.49 92.08 
10 83.54 96.16 
12 98.03 96.87 
                                  
 
Fig 32: Plot of comparative dissolution profile of optimized formulation (F8) and 
Marketed product 
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formulation F9 has better control over release rate in comparison to the 
commercial product.  
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13. SUMMARY 
 
In the present work, 9 different formulations were prepared by direct 
compression, incorporating polymers like Carbopol934, Xanthan gum and HPMC 
K100M as swelling polymers, sodium bicarbonate as gas generating agent, MCC as a 
diluents, talc used as glidant and magnesium stearate used as lubricant.  
  
Characterization of the drug was done by performing the UV spectroscopy and 
IR spectroscopy. IR spectrum of the pure drug was compared with that of physical 
mixture of drug with all the excipients used in the study. The results showed that there 
was no drug-excipient interaction. The UV spectral analysis of the drug solution 
indicated that λmax value as 224 nm. 
 
All the prepared floating formulations were evaluated for hardness, friability, 
uniformity of weight, drug content uniformity, drug-polymer interaction, in-vitro 
floating studies, in vitro drug release and short term stability studies.  
 
  The thickness of the formulations (F1-F9) was in the range of 3.62 + 0.03 to    
3.71 + 0.05mm and the hardness was in the range of 5.3 + 0.2 to 6.1 + 0.3 Kg/ cm2, 
indicated good mechanical strength of the tablets. Friability, weight variation and 
drug content uniformity was found to be within official limits for all the formulations.  
                    The dissolution studies were carried out for 12 hrs. As per the result of 
dissolution study formulation F7, F8 and F9 showed reasonable release respectively. 
But F9 showed good floating lag time and total floating time, when compare to other 
formulations. Based on all these results, formulation F9 was selected as the optimized 
formulation. F9 was then compared to the marketed product and was found that the 
optimized formulation F9 has better control over release rate in comparison to the 
commercial product. 
                   The release kinetics were fitted to different mathematical models like 
Zero order, First order, Higuchi’s and Peppa’s plot. The selected formulation F9 
follows Higuchi’s plot and slope (n) value of Peppa’s for these formulations were 
found to be in the range of “0.45 to 0.85”. This indicates that the drug release depends 
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on swelling, erosion, and diffusion. Thus follows the non-Fickian/anomalous type of 
diffusion. 
                  The drug-polymer ratios, viscosity of polymers, were found to influence 
the drug release and floating properties of the prepared tablets. From the results it can 
be concluded that as the concentration of the polymer increased floating lag time 
decreased and the percentage drug release was prolonged. Viscosity of the polymer 
also showed a directly proportional relationship with swelling characteristics of the 
tablets. 
                 The optimized formulation (F9) was subjected for stability studies as per 
ICH guidelines. Formulations subjected for short term stability studies were checked 
for drug content, hardness, friability and Total floating time for 90 days with an 
interval of 15 days. The formulations were found to be stable as no significant change 
was observed in the various evaluated parameters of the formulations. 
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14. CONCLUSION 
                     Floating Drug Delivery System are retained in the stomach for a longer 
time and assist in improving the oral controlled delivery of drugs that have an 
absorption window in the particular region of the GI tract as well as for controlling 
the release of the drug having site-specific absorption limitation.  
 
         Venlafaxine HCl is a highly effective antidepressant was used as a model 
drug to develop a controlled release formulation. Venlafaxine HCl exhibits pH 
dependent solubility. It is more soluble in acidic pH and slightly soluble at neutral or 
alkaline condition (intestinal environment). Hence an attempt was made to develop 
gastroretentive delivery system of Venlafaxine HCl which increased the 
bioavailability of Venlafaxine HCl and also to reduce frequency of administration, 
thereby improving patient compliance and therapeutic efficacy.  
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